Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)

Andreas Meisel, Carlo Antozzi, Ratna Bhavaraju-Sanka, Jan L. De Bleecker, Wan-Yi Huang, Rosa Hermina Jimenez, Fien M. Verhamme, Ming Jiang, Li Liu, Denis Korobko, Anna Kostera-Pruszczyk, Kimiaki Utsugisawa, Jan J. G. M. Verschuuren, Tuan Vu, Heinz Wiendl, James F. Howard

Open source

DOI: 10.3389/fneur.2026.1876344
Published: 2026-08-21
Container: Frontiers in Neurology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fneur.2026.1876344,
  title = {Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)},
  author = {Andreas Meisel and Carlo Antozzi and Ratna Bhavaraju-Sanka and Jan L. De Bleecker and Wan-Yi Huang and Rosa Hermina Jimenez and Fien M. Verhamme and Ming Jiang and Li Liu and Denis Korobko and Anna Kostera-Pruszczyk and Kimiaki Utsugisawa and Jan J. G. M. Verschuuren and Tuan Vu and Heinz Wiendl and James F. Howard},
  year = {2026},
  journal = {Frontiers in Neurology},
  doi = {10.3389/fneur.2026.1876344},
  url = {https://doi.org/10.3389/fneur.2026.1876344}
}

RIS

TY  - JOUR
TI  - Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)
AU  - Andreas Meisel
AU  - Carlo Antozzi
AU  - Ratna Bhavaraju-Sanka
AU  - Jan L. De Bleecker
AU  - Wan-Yi Huang
AU  - Rosa Hermina Jimenez
AU  - Fien M. Verhamme
AU  - Ming Jiang
AU  - Li Liu
AU  - Denis Korobko
AU  - Anna Kostera-Pruszczyk
AU  - Kimiaki Utsugisawa
AU  - Jan J. G. M. Verschuuren
AU  - Tuan Vu
AU  - Heinz Wiendl
AU  - James F. Howard
PY  - 2026
JO  - Frontiers in Neurology
DO  - 10.3389/fneur.2026.1876344
UR  - https://doi.org/10.3389/fneur.2026.1876344
ER  -

APA

Meisel, A., Antozzi, C., Bhavaraju-Sanka, R., Bleecker, J. L. D., Huang, W., Jimenez, R. H., Verhamme, F. M., Jiang, M., Liu, L., Korobko, D., Kostera-Pruszczyk, A., Utsugisawa, K., Verschuuren, J. J. G. M., Vu, T., Wiendl, H., & Howard, J. F. (2026). Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+). Frontiers in Neurology. https://doi.org/10.3389/fneur.2026.1876344

Source records

crossref · retrieved 2026-09-25T08:52:02.958Z